Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1–8 µM) dose- and time-dep...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Cycle
Autori principali: Prabhu, Varun V., Talekar, Mala K., Lulla, Amriti R., Kline, C. Leah B., Zhou, Lanlan, Hall, Junior, Van den Heuvel, A. Pieter J., Dicker, David T., Babar, Jawad, Grupp, Stephan A., Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Pu, Jeffrey J., Claxton, David F., Khan, Nadia, Oster, Wolfgang, Allen, Joshua E., El-Deiry, Wafik S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927637/
https://ncbi.nlm.nih.gov/pubmed/29157092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1403689
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi